Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: A single-centre experience

Clinical Rheumatology

Volumn 32, Issue 1, 2013, Pages 87-90

  Can, Meryem ^a   Alibaz Öner, Fatma ^a   Yılmaz Öner, Sibel ^a   Atagündüz, Pamir ^a   İnanç, Nevsun ^a   Direskeneli, Haner ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Fast infusion; Rheumatoid arthritis; Rituximab

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 84873405016     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2094-1     Document Type: Article

References (24)

1. Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, De la Serna Rodriguez A, Díaz-López C, Sanmartí R, Nolla JM (2011) Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 29(6):991-997
2. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35-45
3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253-259
4. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P (2010) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J 128(5):309-310
5. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheumatism 63(12):3692-3701
6. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18(17):3135-3143
7. van Vollenhoven RF, Emery P 3rd, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558-567
8. Tuthill M, Crook T, Corbet T, King J, Webb A (2009) Rapid infusion of rituximab over 60 min. Eur J Haematol 82(4):322-325
9. Al Zahrani A, Ibrahim N, Al Eid A (2009) Rapid infusion rituximab changing practice for patient care. J Oncol Pharm Pract 15 (3):183-186
10. Provencio M, Cerdeira S, Bonilla F, Sánchez A, España P (2006) Rapid-infusion rituximab in lymphoma treatment. Ann Oncol 17 (6):1027-1028
11. Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, Alvarez-Larrán A, Besses C (2006) Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 77(4):338-340
12. Atmar J (2010) Review of the safety and feasibility of rapid infusion of rituximab. J Oncol Pract 6(2):91-93
13. Chiang J, Chan A, Shih V, Hee SW, Tao M, Lim ST (2010) A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. Int J Hematol 91(5):826-830
14. Sehn LH,Donaldson J, Filewich A, Fitzgerald C, GillKK, Runzer N, Searle B, Souliere S, Spinelli JJ, Sutherland J, Connors JM (2007) Rapid infusion rituximab in combination with corticosteroidcontaining chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109 (10):4171-4173
15. Larsen JL, Jacobsen S (2012) Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. Rheumatol Int. doi:10.1007/s00296-011- 2208-0
16. Faraawi R, Roth K (2010) Experience with accelerated rituximab infusion for rheumatoid arthritis in a single community practice. Ann Rheum Dis 69(Suppl 3):383
17. Larsen JL, Jacobsen S (2010) Rapid-infusion with rituximab-short term safety in systemic autoimmune disaese. Ann Rheum Dis 69 (Suppl 3):731
18. Bukh G, Larsen S, Rasmussen SS, Hansen MS (2011) Very fast infusion-rate of rituximab for rheumatoid arthritis is well tolerated and safe. Ann Rheum Dis 69(Suppl 3):507
19. Bukh G, Larsen S, Rasmussen SS, Hansen MS (2006) Accelerated infusion-rate of rituximab for rheumatoid arthritis is well tolerated and safe. Rituximab. Full Prescribing Information
20. Rituximab. Full prescribing information (2006), http://www.ema.europa.eu/ . Accessed July 2006
21. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18 (4):509-522
22. Prevoo ML, Van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB et al (1995) Modified disease activity scores that include twenty-eight-joint counts:development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
23. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J et al (2011) Updated consessus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909-920
24. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31(6):456-473